Synonyms: Byfavo® | CNS-7056 | CNS7056
remimazolam is an approved drug (FDA (2020), EMA (2021))
Compound class:
Synthetic organic
Comment: Remimazolam is a benzodiazepine type compound, that was developed as an ultra-short-acting sedative/anesthetic [3-4]. This compound combines the actions of the opioid analgesic remifentanil with that of the currently used sedative midazolam (GABAA receptor modulator). Remimazolam is proposed as a safer alternative to the current standard of care.
|
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2020), EMA (2021)) |
IUPAC Name |
methyl 3-[(4S)-8-bromo-2-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate |
International Nonproprietary Names | |
INN number | INN |
9232 | remimazolam |
Synonyms |
Byfavo® | CNS-7056 | CNS7056 |
Database Links | |
CAS Registry No. | 308242-62-8 |
GtoPdb PubChem SID | 252166652 |
PubChem CID | 9824461 |
Search Google for chemical match using the InChIKey | GHUYIIGPWBMOGY-KRWDZBQOSA-N |
Search Google for chemicals with the same backbone | GHUYIIGPWBMOGY |
Search PubMed clinical trials | remimazolam |
Search PubMed titles | remimazolam |
Search PubMed titles/abstracts | remimazolam |
UniChem Compound Search for chemical match using the InChIKey | GHUYIIGPWBMOGY-KRWDZBQOSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | GHUYIIGPWBMOGY-KRWDZBQOSA-N |